Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
TRIUMPH-1 sponsor-reported topline results
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
PubChem Compound Summary for CID 950107: 5-Amino-1-methylquinolinium
National Center for Biotechnology Information. PubChem CID 950107; record modified July 25, 2026.
Bachem: peptide notation and terminal modifications
Bachem: peptide notation and terminal modifications. Accessed 2026-10-03.
Bachem: Quality Control of Amino Acids and Peptides
Bachem: Quality Control of Amino Acids and Peptides. Accessed 2026-10-05.
Original publication PMID 39555826
Checked 2026-10-06; original study, not NHD batch evidence.
Original publication PMID 38912654
Checked 2026-10-06; original study, not NHD batch evidence.
Thermo Fisher: Peptide Analyzing Tool and its limitations
Checked 2026-10-05; source scope is identified in the article.
Thermo Fisher: Peptide Design guide
Checked 2026-10-05; source scope is identified in the article.
Retatrutide type 2 diabetes trial endpoints
Checked 2026-10-05; source scope is identified in the article.
Agilent: Five Tips for Chromatographic Integration
Agilent: Five Tips for Chromatographic Integration. Accessed 2026-10-05.
Original MOTS-c exercise, aging and muscle-homeostasis study
Checked 2026-10-05; source scope is identified in the article.
Rice et al., eLife (2026): MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide
Original publication; reported findings apply to its study material and model. Checked 2026-10-04.
Thermo Fisher: handling and storage instructions for standard peptides
Thermo Fisher: handling and storage instructions for standard peptides. Accessed 2026-10-03.
REIMAGINE 2 cagrilintide-semaglutide comparative phase 3 study
2026 comparative trial; PMID 42251859.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
MOUNJARO (tirzepatide) current prescribing information
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
AICAR prevents and reverses diabetic polyneuropathy by regulating mitophagy
Experimental study. 2024. PMID 39795939.
FDA Evaluation of AOD-9604-Related Bulk Drug Substances
U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects
Višnjić D, et al. Cells. 2021. PMID 34064363.
Once-weekly cagrilintide for weight management in people with overweight and obesity
Lau DCW, et al. The Lancet. 2021;398:2160–2172. PMID 34798060 · DOI 10.1016/S0140-6736(21)01751-7
Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies
Awosemo O, et al. Journal of Pharmaceutical and Biomedical Analysis. 2021;204:114255. PMID 34304009 · DOI 10.1016/j.jpba.2021.114255
Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle
Neelakantan H, et al. Biochemical Pharmacology. 2019. PMID 30753815 · DOI 10.1016/j.bcp.2019.02.008
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
